AI Article Synopsis

  • Hypereosinophilic syndrome (HES) and immune thrombocytopenic purpura (ITP) can occur alongside ulcerative colitis (UC), but their exact causes are not well understood.
  • Two case studies of UC patients are presented, one who had HES and another with ITP, both of which did not respond to standard treatments.
  • The patients showed significant improvement after undergoing colectomy, indicating that their conditions might be reactive to UC rather than idiopathic.

Article Abstract

Introduction: Hypereosinophilic syndrome (HES) and immune thrombocytopenic purpura (ITP) have been reported to co-occur with ulcerative colitis (UC). However, the exact pathogenic mechanisms of their occurrence remain elusive. In this article, we aim to describe two cases of UC patients who developed refractory HES and ITP and elaborate on their potential pathogenesis.

Case Study: We report two middle-aged patients diagnosed with UC. The first patient developed HES that was refractory to conventional medical therapy of idiopathic HES, and the second developed refractory ITP that failed steroid and immunosuppressive therapy. Both conditions improved considerably following colectomy, suggesting they are of a reactive rather than idiopathic nature.

Conclusion: In patients with UC and refractory comorbid HES or ITP, the reactive nature of these comorbidities should be taken into consideration, and colectomy, therefore, should be considered if clinically indicated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697402PMC
http://dx.doi.org/10.2147/JIR.S365094DOI Listing

Publication Analysis

Top Keywords

developed refractory
12
hypereosinophilic syndrome
8
syndrome immune
8
immune thrombocytopenic
8
thrombocytopenic purpura
8
ulcerative colitis
8
refractory itp
8
resolved hypereosinophilic
4
purpura ulcerative
4
patients
4

Similar Publications

A man in his 60s suffered from refractory, biopsy-proven subacute cutaneous lupus erythematosus that required chronic, moderate dose steroids to manage. His rash was accompanied by arthralgias and negative autoantibody testing. His subacute lupus erythematosus (SCLE) was responsive to tofacitinib, but thrombotic complications limited the use of this medication.

View Article and Find Full Text PDF

Per- and polyfluoroalkyl substances (PFAS) exposure is associated with radioiodine therapy resistance and dedifferentiation of differentiated thyroid cancer.

Environ Pollut

January 2025

State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China; Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:

Differentiated thyroid cancer (DTC) generally has a favorable prognosis, and radioactive iodine (RAI) therapy is typically used for metastatic DTC that continues to progress and poses life-threatening risks. However, resistance to RAI in metastatic DTC significantly impairs treatment effectiveness. This study aims to identify potential compounds that may influence RAI efficacy.

View Article and Find Full Text PDF

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematological malignancies. Recently, CAR-T has been used in refractory auto-immune diseases with initial encouraging results. In this systematic review, we examined the safety and efficacy of CAR-T in patients with refractory auto-immune diseases.

View Article and Find Full Text PDF

Aims: Drug-refractory epilepsy (DRE) refers to the failure of controlling seizures with adequate trials of two tolerated and appropriately chosen anti-seizure medications (ASMs). For patients with DRE, surgical intervention becomes the most effective and viable treatment, but its success rate is unsatisfactory at only approximately 50%. Predicting surgical outcomes in advance can provide additional guidance to clinicians.

View Article and Find Full Text PDF

Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy.

Int J Biol Macromol

January 2025

Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.

Acute myeloid leukemia (AML) is a severe blood cancer with an urgent need for novel therapies for refractory or relapsed patients. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), an immune suppressive receptor expressed on immune cells and AML blasts but minimally on hematopoietic stem cells (HSCs), represents a potential therapeutic target. But there has been limited research on therapies targeting LAIR1 for AML and no published reports on LAIR1 antibody-drug conjugate (ADC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!